Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice.
Biotechnol Lett
; 31(11): 1685-93, 2009 Nov.
Article
en En
| MEDLINE
| ID: mdl-19579009
ABSTRACT
The immunogenicity of SARS-CoV nucleocapsid DNA vaccine and the immunoregulatory activity of interleukin-2 (IL-2) were investigated. DNA vaccine plasmids, pcDNA-N and pcDNA-IL2, were constructed and inoculated into BALB/c mice with or without pcDNA-IL2 by intramuscular injection. Cellular and humoral immune responses were assessed by indirect ELISA, lymphocyte proliferation assays, ELISPOT and FACS. The nucleocapsid DNA vaccine had good immunogenicity and can induce specific humoral and cellular immunity in BALB/c mice, while IL-2 plays an immunoadjuvant role and enhances specific immune responses. This study provides a frame of reference for the design of DNA vaccines against SARS-CoV.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Interleucina-2
/
Vacunación
/
Nucleocápside
/
Vacunas de ADN
/
Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo
/
Vectores Genéticos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Biotechnol Lett
Año:
2009
Tipo del documento:
Article